SHU T T E RSTOCK/C& E N
COVER STO RY
DIVERGING ROADS FOR MICRODOSING SUBTHERAPEUTIC DOSES in drug development tests have shown
important—but unanticipated—advantages CELIA HENRY ARNAUD, C&EN WASHINGTON
WHEN MICRODOSING WAS the next big
thing—back in the early to mid-2000s— drug developers had great plans for it. One of the problems with drug development is that failures often happen late in the development process. Microdosing offered a way to identify potential failures earlier, before full-fledged clinical trials. Researchers would give subtherapeutic doses to humans after minimal animal testing and use those doses to figure out how the drug behaved in the body. If the drug didn’t behave as desired, they would move on to the next candidate and save themselves the trouble of doing extensive safety testing. Some industry observers predicted that microdosing would become a standard part of the drug development process. It would give them greater confidence in the candidates that advanced to clinical trials. At that point, they could do the safety testing required for therapeutic doses, secure in the knowledge that they had a winner.
But those plans didn’t work out quite as expected. Microdosing still has a place in the drug development process, but it’s being used in ways that people didn’t anticipate. Today microdoses—defined as 1% of a pharmacologically active dose but no more than 100 µg—are used primarily in two types of studies. Absolute bioavailability studies are performed in parallel with standard clinical trials to determine what fraction of the therapeutic dose actually reaches systemic circulation. And so-called Phase 0 studies are early human clinical trials designed to weed out drug failures early in the process, before the conventional safety and efficacy testing required for regulatory approval. People originally thought the industry would adopt microdosing for Phase 0 trials. Such trials do happen occasionally but not nearly to the extent that people had predicted. In contrast, microdose absolute bioavailability studies are on
W W W.CEN- ONLI NE.ORG
9
JANUARY 21, 20 13
their way to becoming an industry norm. And other uses may be yet to come. From its earliest days, microdosing has been associated with a particular analytical method—accelerator mass spectrometry. In AMS, ions are accelerated to kinetic energies that are high enough to separate individual elemental isotopes. AMS’s hallmark characteristic is its sensitivity, which is sufficient to measure low levels of rare isotopes such as carbon-14. Because the radiolabeled drugs are the only source of carbon-14, AMS allows researchers to quantify them and their metabolites in the body, but it doesn’t provide the molecular information necessary to identify the individual compounds. But microdosing has become platform independent. “AMS was the tool that propelled microdosing, because it had the sensitivity,” says Stephen R. Dueker, chief scientific officer at Vitalea Science, an AMS services company in Davis, Calif., that was
COVER STO RY
ACC I U M B I OSC I E N C ES
acquired last September by the German company Eckert & Ziegler. Now microdosing can be done with any technique sensitive enough to detect the drug in biological samples. Some companies are turning to conventional liquid chromatography/tandem mass spectrometry (LC/MS/MS) for microdosing studies. “I’m not naive enough to think that we can beat AMS in sensitivity,” says Jack Henion, chief scientific officer at Advion Bioanalytical Laboratories, a Quintiles company and an Ithaca, N.Y-based contract research organization that is developing ultratrace LC/MS/MS techniques for the analysis of biological samples collected from microdosing studies. But he does think that LC/MS/MS can surpass AMS in terms of workflow issues such as sample preparation and integration of separations. Relative to AMS, LC/ MS/MS does have other drawbacks for microdosing studies. Scientists need to be able to follow the drug as it is metabolized and excreted. That requires an assay for each metabolite—assuming that all the metabolites have been identified. Plus, the different elimination products—such as urine and feces—can respond differently in the mass spectrometer, making quantitation difficult. However, LC/MS/ MS does provide molecular information about the drug and its metabolites, not just radiolabel identification. PHARMACEUTICAL companies are also
exploring the use of LC/MS/MS for microdosing studies. For example, last September Li Sun and coworkers from Merck Research Laboratories reported that they used LC/MS/MS to quantify five HIV-1 integrase inhibitors in human plasma during a microdose clinical trial (Anal. Chem., DOI: 10.1021/ac301581h). They calculated pharmacokinetic parameters such as halflife and clearance and determined that the microdoses could be used to extrapolate to the pharmacologic doses. Even as the methods used for microdosing have evolved, regulatory barriers have fallen. The U.S. Food & Drug Administration cleared the way for companies to implement Phase 0 microdosing studies in 2006. But
the uptake “has been much slower than expected,” says Christopher C. Kelly, a spokesman for FDA’s Center for Drug Evaluation & Research. “In our experience, there has been more enthusiasm for microdosing in Europe than in the U.S.” One hurdle that has hindered uptake of Phase 0 studies is skepticism that the pharmacokinetic properties observed at microdoses would accurately predict those properties at therapeutic doses. “At the beginning, people were very skeptical. They felt they knew of too many cases where small doses of drugs don’t predict the higher doses you might need for a
far microdosing is much more predictive. However, when somebody does a microdose study, they always ask the same question: Can you guarantee that the microdose will give you the right answer? Of course, the answer is no, you can’t guarantee,” Lappin says. “I’m a bit bewildered why the question is still being asked to the degree that it was 10 years ago.” But the alternative methods are at best 50% predictive, he says. A BIGGER HINDRANCE to adoption is the
time and money that Phase 0 trials add to drug development. “If you find that a molecule looks very promising, you still have to go back and do all the safety assessment before you start giving pharmacologic doses to humans,” Rowland says. “It doesn’t save you time if you are confident that you have got a winner.” Where it may save time, Rowland says, is advancing backup compounds after failure of a lead compound in Phase I trials. CAREFUL DOSAGE Although microdose trials Many microdosing can help prioritize candiexperiments need dates, the value of that inforthe sensitivity of accelerator mass mation may not be enough to spectrometry. make the approach attractive. Pharma companies take the attitude that, “I’ve just added a whole study in the middle of my developpharmacological response,” says Malcolm ment that I never did,” says Ali Arjomand, Rowland, a pharmaceutical scientist at the president and chief operating officer of University of Manchester, in England, and Accium BioSciences, a Seattle-based AMS the University of California, San Francisco. services company. Pharmaceutical com“There was a lot of headwind to be overpanies are more likely to take the risk of come before people would think about usmoving multiple candidates to Phase I than ing microdosing.” spend the time and money on Phase 0 trials, European trials of microdosing conArjomand says. ducted in the mid-2000s—the European “Most pharmaceutical companies don’t Union Microdosing AMS Partnership have their own accelerator mass spectromProgramme and the Consortium for Reeter, and the analysis can be quite expensourcing & Evaluating AMS Microdosing— sive,” says Lisa Christopher, a biotransforsuggest that for a majority of compounds mation scientist at Bristol-Myers Squibb. such worries are unfounded. Rowland “We judiciously decide whether there is a and Graham Lappin were involved in both cost savings or other advantage before we studies. Lappin, formerly the chief sciendo the study.” tific officer of Xceleron, is now reader of Phase 0 microdosing “is being done on pharmaceutical science at the University of a case-by-case basis, when it answers a Lincoln, in England, and adjunct professor specific question,” Vitalea’s Dueker says. at Duke University. Such trials have shown “We all expected it to be part of the regular microdosing to be predictive in 70 to 80% clinical development path.” But it didn’t of cases, Lappin says. work out that way, he notes. “It’s not really a “If you put microdosing in the context routine tool for any company I know.” of the best alternative methods, then so W W W.CEN- ONLI NE.ORG
10
JANUARY 21, 20 13
“Did I make my compound?” – Answer in seconds
The expression Compact Mass Spectrometer (CMS) offers an immediate answer to this question for more chemists than ever before. Priced substantially lower than other available systems, the expression brings analytical confidence to routine chemistry processes not possible with other detection techniques.
Ideal for chemists who need mass analysis for: UÊReaction
monitoring (by Flow Injection Analysis or LC)
UÊMass
monitoring with Normal Phase Flash Chromatography
UÊMass
analysis of Flash fractions
UÊMass
Confirmation
UÊPeptide
Synthesis
UÊCleaning
validation
UÊFlow
Synthesis
UÊImpurity UÊIC
analysis www.expressioncms.com |
[email protected] NEW
Chemicals, Inc.
P-Ligands New
An Employee-Owned Company Serving Customers Globally
Et
Established 1964
Though Rowland doesn’t expect Phase 0 trials to become a routine part of the drug development process, he thinks that they may be more common than people realize. “I think in reality microdosing is employed within companies, but we won’t necessarily hear about these very early-stage studies,” he says. Indeed, Graeme Young, a scientist at GlaxoSmithKline, the only pharmaceutical company with its own AMS instruments, says that GSK has conducted several microdosing studies. “We’ve tried to use it in decision making in certain circumstances rather than use it as a scattergun approach for all projects,” he says. For example, GSK has used microdosing to identify drug-drug interactions. Another circumstance in which microdose trials become attractive is when animal studies are giving contradictory information. “The rat might be telling you one thing, and the dog is telling you something else,” Young says. “Which one do I believe is going to be reflective of the human situation?” That’s when people start to consider microdosing, he says.
Et
Et
Et O
C H
O
P
C O
C H
O
Et
P
CH3
C6H11
N
CH3
C6H11
Et
15-1517 Et Taddol P-Lig
15-0445 PhenCar-Phos
Et
(H3C)3C
P
C(CH3)3
Cl
P
COMPANIES MAY NOT have adopted microdosing for Phase 0 N
15-1095 P-Lig
H3C
trials, but they have embraced what some have called microdosing for absolute bioavailability studies. It involves the use of an intravenous reference dose. Such studies allow scientists to determine what fraction of a therapeutic dose of their drug candidate reaches systemic circulation in a patient. (Lappin and Rowland both caution that because the pharmacokinetics in such studies is driven by the pharmacologic doses, such intravenous doses are more accurately called tracer doses than microdoses.) In these studies, a therapeutic dose of a drug is administered via the intended route, usually oral but sometimes via another route such as inhalation or through the skin. When the drug reaches its maximum systemic concentration, an isotopically labeled microdose of the drug is administered intravenously. The IV dose is 100% bioavailable. By referring to the IV profile, researchers can calculate the fraction of drug available via its normal route of administration. The pharmacokinetics of the IV dose is driven by the concentration already in the bloodstream from the oral dose, Lappin explains. This means that unlike Phase 0 trials, in microdose absolute bioavailability studies there are no concerns about whether the microdose pharmacokinetics scale linearly with the therapeutic dose. Conventional absolute bioavailability studies are much harder to do. For those studies, researchers give participants an oral dose at the therapeutic concentration and quantify drug levels in plasma. After a two- or three-week “washout” period, they give the same subjects an intravenous dose, also at the therapeutic level, which sets the 100% value. The ratio of the respective integrated pharmacokinetic plots reveals the absolute bioavailability of the oral dose. But giving such a large IV dose comes with safety and formulation concerns. The drug may not be soluble at such high concentrations. Figuring out how to make it soluble can add time and cost, Arjomand says. Then, that new formulation has to undergo additional safety and toxicity studies. “It’s basically a new drug, a new route of administration,” he says. “All these aspects have added cost, time, and risk. These absolute bioavailability studies have always been a challenge, and companies have tended to do them later if they can.” But with microdose absolute bioavailability studies, these concerns vanish. The IV dose, which is given on top of the therapeutic dose, is small enough that the safety testing for therapeutic dose is sufficient. “Because it’s just a small fraction of what’s being
15-1248 CH3 AMPHOS
See www.strem.com/new_products Corporate Headquarters Newburyport, MA 01950
Europe 67800 Bischheim, France
email:
[email protected] email:
[email protected] www.strem.com
The
uture is here.
The pHit Handheld Scanner. The world’s first calibration-free, non-glass, dry-storage pH meter. Learn more and get yours at SenovaSystems.com.
W W W.CEN- ONLI NE.ORG
12
JANUARY 21, 20 13
COVER STO RY
“There was a lot of headwind to be overcome before people would think about using microdosing.” absorbed orally, it’s not considered an additional toxicological concern or safety concern,” Dueker says. The IV dose must be labeled so it can be distinguished from the pharmacologic dose. Often the IV dose is radiolabeled with carbon-14, and AMS is used to detect it. However, with enough sensitivity, LC/MS/MS can be used to detect IV doses labeled with carbon-13, says Xiaohui (Sophia) Xu, a bioanalytical scientist at Bristol-Myers Squibb. Microdose absolute bioavailability studies have become a standardized process at BMS, Xu says. “The IV microdosing strategy is widely applied in late-stage small-molecule oral compounds,” she says. Likewise, the absolute bioavailability study design is “gaining ground” at GSK, Young says. GSK has conducted five such studies so far. “This is the way the industry is going,” Young says. “It’s relatively inexpensive as clinical studies go. If you do it right, you can add the IV arm on a clinical study you’ve already got in place. You get a lot of information out of that study design for a relatively small investment.” Still, Arjomand says, “we definitely are in the early days” for absolute bioavailability studies. “Some pharma companies are completely sold and are moving more and more of their compounds into this paradigm.” If regulatory authorities start requiring such studies, many more companies will have to follow the early adopters, he predicts. OTHER MICRODOSING applications
could be down the road. Paul T. Henderson uses microdosing combined with AMS to determine if cancer patients are good candidates for platinum-based therapies. Henderson is a researcher at the UC Davis Medical Center and chief executive officer of Accelerated Medical Diagnostics. For the diagnostic test, Henderson gives a patient a C-14-labeled microdose of the therapeutic one or two days before a scheduled biopsy. During the biopsy, he takes blood samples and some of the leftover biopsy material. He extracts DNA from the blood and tissue and analyzes it with AMS to see how much the drug has modified the DNA. He and his coworkers are undertaking two clinical trials, with different drugs
and patient populations, to determine the level of DNA modification that indicates a patient is a good candidate for the drug. He expects the level to be between just a few
drug-DNA adducts per genome per cell. And there’s surely more to come, Lappin says. “I think there are applications of microdosing that have yet to emerge.” ◾
Discover The Uniqueness of Spectrum! 2013 - 2014 Organic Chemical Catalog
2013 - 2015 USP Chemical Catalog 1,200 USP/NF/FCC Chemicals Largest USP Offering Ever!
22,000 TCI Organic Chemicals Specialists in Organic Research
Depend on Spectrum, We Deliver from Stock! Contains various Chemical Lists, such as a list for Alzheimer’s Research, Obesity Research, Vitamins, Amino Acids, Oils, etc.
Request Your FREE Copy! SpectrumChemical.com/Request_Catalog
800.772.8786 SpectrumChemical.com W W W.CEN- ONLI NE.ORG
13
JANUARY 21, 20 13
